OTLK
NASDAQ HealthcareOutlook Therapeutics, Inc. - Common Stock
Biotechnology
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
�� 市场数据
| 价格 | $0.81 |
|---|---|
| 成交量 | 18,488,561 |
| 市值 | 120.89M |
| 贝塔系数 | 0.330 |
| RSI（14日） | 88.9 超买 |
| 200日均线 | $0.94 |
| 50日均线 | $0.30 |
| 52周最高 | $3.39 |
| 52周最低 | $0.16 |
| Forward P/E | -3.05 |
| Price / Book | -2.94 |
🎯 投资策略评分
OTLK 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (98/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 OTLK in your text
粘贴任何文章、记录或帖子 — 工具将提取 OTLK 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.